CPT Code Overview

CPT 81469 is a genomic sequence analysis panel for hereditary breast cancer-related disorders, requiring sequencing of at least 14 genes (for example, ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53).

Service Type: Genetic Testing

Typical Site of Service: Laboratory (POS 81)

Clinical Context

A 42-year-old woman with a personal history of early-onset breast cancer and a family history of breast and ovarian cancer is referred for genetic testing to evaluate hereditary breast cancer-related disorders. The clinical workflow: a genetics or oncology provider documents the indication (for example, genetic susceptibility to malignant neoplasm of breast Z15.01 or family history Z80.3), obtains informed consent, and orders a genomic sequencing panel that includes at least 14 genes (e.g., BRCA1, BRCA2, PALB2, TP53). A specimen is collected at the outpatient clinic or sent directly from the office to the laboratory (typical site of service: laboratory POS 81). The laboratory performs the sequencing analysis and reports pathogenic, likely pathogenic, and variants of uncertain significance. Results are returned to the ordering provider for interpretation and management planning; a genetics professional with an appropriate taxonomy may provide counseling.

Coding Specifications

• Common modifiers:

• 26: Professional Component — used when reporting only the professional component of the service (interpretation by a qualified professional).

• 59: Distinct Procedural Service — used when this test is performed and a separately identifiable service/test is provided on the same day that is not normally reported together.

• Associated provider taxonomies and specialties:

• Notes on component reporting:

• The laboratory technical component (sequencing, bioinformatics, and reporting) is typically included in the contracted laboratory fee; when only the professional interpretation is billed separately, 26 may be appended.

• Use 59 when an additional distinct procedure or test is performed the same day that is not typically bundled with the panel.

Related Diagnoses

• Z15.01 — Genetic susceptibility to malignant neoplasm of breast

Associated with ordering hereditary breast cancer panels to evaluate inherited risk and identify actionable germline variants.

• C50.919 — Malignant neoplasm of unspecified site of unspecified female breast

Relevant when a patient has breast cancer and tumor/clinical history prompts germline testing for hereditary cancer predisposition.

• Z80.3 — Family history of malignant neoplasm of breast

Used when family history of breast cancer raises concern for hereditary syndromes and supports panel testing.

• Z84.81 — Family history of carrier of genetic disease

Applied when an individual’s family history indicates known carrier status in relatives, prompting consideration of targeted or panel genetic testing.

• Z15.02 — Genetic susceptibility to malignant neoplasm of ovary

Relevant because hereditary breast cancer-related panels often include genes (e.g., BRCA1/BRCA2) that confer ovarian cancer risk, supporting combined hereditary risk assessment.

Related CPT Codes

• Common use patterns:

• Panels such as 81469 are commonly used instead of single-gene tests like 81211 when broader gene coverage is clinically indicated.

• 81433 may be ordered alongside 81469 when duplication/deletion analysis is required and not fully captured by sequencing alone.

• 81213 is used as a targeted alternative when a specific familial variant is known and sequencing the full panel is not necessary.

National commercial mean rates for Blue Cross Blue Shield and BUCA are identical at $80.02 for CPT 81469, while Medicare data is not provided in the input. This places the documented commercial average on par with the BUCA benchmark; no separate Medicare mean is available for direct comparison.

Dispersion across the reported payers is minimal where data exists: the 25th, 50th, and 75th percentiles for both Blue Cross Blue Shield and BUCA are all $80.00, yielding a P75–P25 range of $0.00 and indicating a very tight distribution. Other payers have no data available in the input. The table and chart below present the full breakdown of national mean and percentile values.